Aktieanalys

Magle Chemoswed Q3 2023: DSM business advancements - Redeye

Redeye Publicerad: 26 Oct 2023 09:49

Redeye leaves a comment on the Q3 report published by Magle yesterday. Overall, the report was in line with our expectations. While net sales came in slightly below our expectations due to a slower quarter for the contract manufacturing business, we are encouraged by the continuously growing sales from the DSM segment. We reiterate our previous fair value range (SEK25 – SEK58) with a base case valuation of SEK40 as we continue to have a positive outlook on the case.

Länk till analysen i sin helhet: https://www.redeye.se/research/950357/magle-chemoswed-q3-2023-dsm-business-advancements?utm_source=finwire&utm_medium=RSS

Nyheter om Magle Chemoswed

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!